TITLE

Current and emerging therapies for patients with advanced non-small-cell lung cancer

AUTHOR(S)
Sheth, Sheetal
PUB. DATE
January 2010
SOURCE
American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, pS9
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. To review recent clinical trials that have examined new options for the treatment of non-small-cell lung cancer (NSCLC) and to review the importance of tumor histology and genetics in the selection of therapy. Summary. Targeted biological agents have been evaluated for use in patients with NSCLC. In a recent study, treatment with cetuximab plus chemotherapy led to significant improvement in overall survival (OS) in patients with advanced NSCLC. A Phase III, noninferiority, randomized study evaluating first-line therapy in patients with stage IIIb or IV NSCLC demonstrated that the combination of cisplatin and pemetrexed was noninferior to cisplatin and gemcitabine in improving OS and other clinical outcomes. In this study, the combination of pemetrexed and cisplatin was effective in patients with nonsquamous disease, whereas the combination of cisplatin and gemcitabine was effective in improving progression-free survival (PFS) in patients with squamous cell carcinoma. Clinical trials of maintenance therapy presented at the 2009 annual meeting of the American Society of Clinical Oncology reported significant benefit of pemetrexed in patients with nonsquamous tumor histology, and of erlotinib in patients with squamous and nonsquamous histology. For second-line therapy, studies of the investigational tyrosine kinase inhibitor, vandetanib, failed to demonstrate improved OS with vandetanib in combination with docetaxel or pemetrexed, or in direct comparison with erlotinib. In another study, the addition of bevacizumab to erlotinib for second-line treatment of NSCLC did not result in greater OS than erlotinib alone. Conclusion. New treatment strategies are needed to improve clinical outcomes for patients with advanced NSCLC. The introduction of new agents with improved tolerability profiles has led to interest in long-term maintenance therapy in this patient population. Clinical trials suggest that tumor histology and genetics should be considered when selecting treatments for these patients.
ACCESSION #
47427264

 

Related Articles

  • Traitement des cancers bronchiques à petites cellules métastatiques en 2012. Baize, N. // Oncologie;May2012, Vol. 14 Issue 5, p320 

    Systemic chemotherapy plays a major role in the management of patients with Stage IV small-cell lung cancer(SCLC). Despite strong initial chemosensitivity, majority of patients relapse within a few months and few patients survive more than a year. Spontaneous prognosis is wrong for at least six...

  • Surgery in limited-disease small-cell lung cancer. Koul, Parvaiz A. // Lung India;Jan-Mar2012, Vol. 29 Issue 1, p2 

    The author reflects on the abandonment of surgery as a treatment of choice for patients with limited-disease small-cell lung cancer (LD-SCLC) due to the result of a randomized trial which revealed a survival difference between surgery and radiotherapy. An overview of some studies which show that...

  • Phase 4 SAiL confirms safety profile of first-line bevacizumab in nonsquamous NSCLC.  // Hem/Onc Today;8/25/2010, Vol. 11 Issue 16, p8 

    This article reports on the positive results obtained by the Safety of Avastin in Lung (SAiL) trial which examined the safety profile of first-line bevacizumab in the treatment of nonsquamous non-small cell lung cancer.

  • Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer. Reck, Martin; von Pawel, Joachim; Macha, Hans-Nicolas; Kaukel, Eckhard; Deppermann, Karl-Matthias; Bonnet, Reiner; Ulm, Kurt; Hessler, Sybill; Gatzemeier, Ulrich // JNCI: Journal of the National Cancer Institute;8/06/2003, Vol. 95 Issue 15, p1118 

    Cites the results of a randomized phase III trial from 1998 to 1999 comparing the efficacy of carboplatin, etoposide and paclitaxel and of vincristine, etoposide and carboplatin in treating small-cell lung cancer. Patient eligibility; Treatment protocol; Treatment evaluations and statistical...

  • Use of histological and genetic markers in optimizing therapy for patients with non-small-cell lung cancer. Adams, Val R.; Harvey, R. Donald // American Journal of Health-System Pharmacy;1/1/2010, Vol. 67 Issue 1, pS3 

    Purpose. To describe how molecular and genetic markers influence the response to therapy in patients with advanced nonsmall- cell lung cancer (NSCLC). Summary. Cisplatin resistance has been associated with high rates of expression of endonucleases, a family of DNA repair proteins that includes...

  • Millennium Pharmaceuticals: more Velcade ventures.  // PharmaWatch: Biotechnology;Apr2006, Vol. 5 Issue 4, p5 

    The article reports on the launch of a phase II trial of Velcade in combination with pemetrexed in non-small lung cancer (NSCLC) initiated by Millennium Pharmaceuticals Inc. and Johnson & Johnson in 2006. The trial will study the effects of Velcade in patients with NSCLC who have failed prior...

  • Advances of Treatment of Small Cell Lung Cancer in 2012 American Society of Clinical Oncology Annual Meeting. Kan Wu; Bing Xia; Shenglin Ma // Chinese Journal of Lung Cancer;Nov2012, Vol. 15 Issue 11, p672 

    No abstract available.

  • Lung cancer imaging agent.  // FDA Consumer;Nov96, Vol. 30 Issue 9, p5 

    Announces the availability of the Nofetumomab, an agent that can determine the extent of disease in patients diagnosed with small cell lung cancer (SCLC). Benefits in using the product; Restrictions on the use of the product; Statistics on the number of patients diagnosed with SCLC in the...

  • Erlotinib/ciprofloxacin.  // Reactions Weekly;4/14/2012, Issue 1397, p16 

    The article describes the case of a 79-year-old man who developed fatal interstitial lung disease [ILD] while receiving erlotinib for non-smallcell lung cancer [NSCLC]. He also developed an increase in erlotinib concentrations after receiving ciprofloxacin

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics